Details for New Drug Application (NDA): 215029
NDA 215029 describes BONDLIDO, which is a drug marketed by Medrx Usa and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the BONDLIDO profile page.
The generic ingredient in BONDLIDO is lidocaine. There is one drug master file entry for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the lidocaine profile page.
The generic ingredient in BONDLIDO is lidocaine. There is one drug master file entry for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the lidocaine profile page.
Pharmacology for NDA: 215029
| Physiological Effect | Local Anesthesia |
Medical Subject Heading (MeSH) Categories for 215029
Suppliers and Packaging for NDA: 215029
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| BONDLIDO | lidocaine | SYSTEM;TOPICAL | 215029 | NDA | Terrain Pharmaceuticals, Inc. | 53225-1111 | 53225-1111-3 | 28 POUCH in 1 CARTON (53225-1111-3) / 1 PATCH in 1 POUCH (53225-1111-1) / 1 SYSTEM in 1 PATCH |
| BONDLIDO | lidocaine | SYSTEM;TOPICAL | 215029 | NDA | MEDRx USA, Inc. | 83708-111 | 83708-111-01 | 1 CARTON in 1 PATCH (83708-111-01) / 28 SYSTEM in 1 CARTON (83708-111-28) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SYSTEM;TOPICAL | Strength | 10% | ||||
| Approval Date: | Sep 24, 2025 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Sep 24, 2028 | ||||||||
| Regulatory Exclusivity Use: | NEW PRODUCT | ||||||||
| Patent: | 8,722,065 | Patent Expiration: | Nov 10, 2028 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
